We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$71.3B
1-Year Est. Return
56.8%
This Fund
S&P 500
This Quarter
Est. Return
+24.89%
1 Year Est. Return
+56.8%
3 Year Est. Return
+170.28%
5 Year Est. Return
+249.16%
10 Year Est. Return
+1,007.9%
AUM
$71.3B
AUM Growth
+$6.48B
(+10%)
Cap. Flow
-$2.43B
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
29.48%
Holding
1,130
New
174
Increased
291
Reduced
392
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Devon Energy
DVN
|
+$353M |
| 2 |
Marvell Technology
MRVL
|
+$150M |
| 3 |
Spyre Therapeutics
SYRE
|
+$126M |
| 4 |
BridgeBio Pharma
BBIO
|
+$116M |
| 5 |
Dover
DOV
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$713M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$355M |
| 3 |
CTRA
Coterra Energy
CTRA
|
+$289M |
| 4 |
Royalty Pharma
RPRX
|
+$259M |
| 5 |
Eli Lilly
LLY
|
+$236M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.29% |
| 2 | Healthcare | 14.03% |
| 3 | Financials | 12.39% |
| 4 | Industrials | 8.94% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
676
LyondellBasell Industries
LYB
$20.8B
| $12.1M | 0.02% |
230,100
+400
| +0.2% | +$27.6K |
|
677
IAMGOLD
IAG
$11.7B
| $12M | 0.02% |
760,000
-290,000
| -28% | -$5.07M |
|
678
Ionis Pharmaceuticals
IONS
$9.31B
| $11.9M | 0.02% |
150,000
+100,000
| +200% | +$7.53M |
|
|
GTM
679
ZoomInfo Technologies
GTM
$1.08B
| $11.7M | 0.02% |
4,000,000
-750,000
| -16% | -$3.37M |
|
680
Regency Centers
REG
$13.8B
| $11.7M | 0.02% |
146,900
| – | – |
|
|
BLD
681
DELISTED
TopBuild
BLD
| $11.7M | 0.02% |
33,000
-92,000
| -74% | -$37.9M |
|
682
Aptiv
APTV
$9.24B
| $11.6M | 0.02% |
188,600
-176,200
| -48% | -$10.8M |
|
683
Ring Energy
REI
$386M
| $11.5M | 0.02% |
+10,650,000
| New | +$14.8M |
|
684
Kimco Realty
KIM
$15.8B
| $11.4M | 0.02% |
451,063
-150,400
| -25% | -$3.61M |
|
685
McCormick & Company Non-Voting
MKC
$13.8B
| $11.4M | 0.02% |
226,330
+100
| +0% | +$4.91K |
|
686
Oric Pharmaceuticals
ORIC
$1.3B
| $11.4M | 0.02% |
1,051,903
+707,588
| +206% | +$6.42M |
|
687
TKO Group
TKO
$14B
| $11.3M | 0.02% |
56,100
-3,000
| -5% | -$585K |
|
|
BETA
688
Beta Technologies Inc
BETA
$4.71B
| $11.3M | 0.02% |
672,505
-911,089
| -58% | -$15.2M |
|
|
LFAC
689
Leapfrog Acquisition Corp
LFAC
| $11.2M | 0.02% |
1,125,000
| – | – |
|
690
Huntington Ingalls Industries
HII
$11.1B
| $11.2M | 0.02% |
40,107
+100
| +0.2% | +$33.4K |
|
691
Corvus Pharmaceuticals
CRVS
$1.12B
| $11.2M | 0.02% |
750,000
| – | – |
|
692
Zebra Technologies
ZBRA
$16.3B
| $11.2M | 0.02% |
42,411
-1,500
| -3% | -$353K |
|
693
MetLife
MET
$60.8B
| $11.1M | 0.02% |
+131,726
| New | +$10.6M |
|
|
BWIV
694
Blue Water Acquisition Corp IV
BWIV
$177M
| $11.1M | 0.02% |
+1,125,000
| New | +$11.1M |
|
|
APMC
695
AmperCap Acquisition Co
APMC
$199M
| $11.1M | 0.02% |
+1,125,000
| New | +$11.1M |
|
696
CDW
CDW
$17.8B
| $11.1M | 0.02% |
78,900
+7,700
| +11% | +$967K |
|
697
Pentair
PNR
$9.18B
| $11M | 0.02% |
144,002
+38,000
| +36% | +$3.01M |
|
|
IPFX
698
Inflection Point Acquisition Corp VI
IPFX
$339M
| $11M | 0.02% |
+1,066,678
| New | +$11M |
|
|
BBCQ
699
DELISTED
Bleichroeder Acquisition Corp II
BBCQ
| $11M | 0.02% |
1,068,599
-1,181,401
| -53% | -$12.2M |
|
700
Boston Properties
BXP
$10.3B
| $11M | 0.02% |
165,543
-54,400
| -25% | -$3.26M |
|
Similar funds
Adage Capital Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Adage Capital Partners held 1,130 positions worth $71.3B, up 10% from $64.8B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Adage Capital Partners withdrew a net $2.43B in Q2 2026, closing 128 positions and reducing 392 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $355M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Marvell Technology worth $222M.
- Adage Capital Partners's largest Q2 2026 buy was Marvell Technology: 745,800 shares worth $222M.
- Adage Capital Partners added most to Devon Energy in Q2 2026, an estimated $353M increase.
- Adage Capital Partners's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $713M.
- Adage Capital Partners fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $355M.
- Adage Capital Partners's ten largest holdings make up 29% of its $71.3B portfolio in Q2 2026.
- Adage Capital Partners opened 174 new positions and closed 128 in Q2 2026.
- Adage Capital Partners's portfolio value rose 10% quarter-over-quarter to $71.3B.
Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.